Digital x-ray developer Swissray International expanded its product line with the 1999 RSNA introduction of ddRChest-System and ddRCombi, a digital x-ray unit aimed at emergency room/trauma centers. Both systems employ Swissray’s ddR-Bucky CCD-based
Digital x-ray developer Swissray International expanded its product line with the 1999 RSNA introduction of ddRChest-System and ddRCombi, a digital x-ray unit aimed at emergency room/trauma centers. Both systems employ Swissrays ddR-Bucky CCD-based digital detector.
ddRChest-System can employ a 30kW or 50kW x-ray generator and can be ready for exposure every five seconds, according to the New York City-based firm. The unit also utilizes the vendors SwissVision workstation.
ddRCombi is available in three different configurations. ddRCombi Automatic features a motorized vertical and horizontal ceiling suspension system, while ddRCombi Manual offers a manual ceiling suspension system. ddRCombi Solo allows users to bring digital technology to an existing tube stand system, according to Swissray. All three configurations employ an 80kW generator and Swissrays ddR patient table.
Both ddRCombi and ddRChest-System have received the necessary Food and Drug Administration clearances, according to Swissray. ddRChest-System will begin shipping in the second quarter of 2000 and will have a price range of $360,000 to $375,000. ddRCombi will ship in either the second or third quarter and will have a price range of $350,000 to $650,000.
GE HealthCare Debuts AI-Powered Cardiac CT Device at ACC Conference
April 1st 2025Featuring enhanced low-dose image quality with motion-free images, the Revolution Vibe CT system reportedly facilitates improved diagnostic clarity for patients with conditions ranging from in-stent restenosis to atrial fibrillation.
The Reading Room Podcast: Current Perspectives on the Updated Appropriate Use Criteria for Brain PET
March 18th 2025In a new podcast, Satoshi Minoshima, M.D., Ph.D., and James Williams, Ph.D., share their insights on the recently updated appropriate use criteria for amyloid PET and tau PET in patients with mild cognitive impairment.